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Abstract
Objective To assess if very elderly people with hypertension obtain
early benefit from antihypertensive treatment.
Design One year open label active treatment extension of randomised
controlled trial (Hypertension in the Very Elderly Trial (HYVET)).
Setting Hospital and general practice based centres mainly in eastern
and western Europe, China, and Tunisia.
Participants People on double blind treatment at the end of HYVET
were eligible to enter the extension.
Interventions Participants on active blood pressure lowering treatment
continued taking active drug; those on placebo were given active blood
pressure lowering treatment. The treatment regimen was as used in the
main trial—indapamide SR 1.5 mg (plus perindopril 2-4 mg if
required)—with the same target blood pressure of less than 150/80 mm
Hg.
Main outcome measures The primary outcome was all stroke; other
outcomes included total mortality, cardiovascular mortality, and
cardiovascular events.
Results Of 1882 people eligible for entry to the extension, 1712 (91%)
agreed to participate. During the extension period, 1682 patient years
were accrued. By six months, the difference in blood pressure between
the two groups was 1.2/0.7 mmHg. Comparing people previously treated
with active drug and those previously on placebo, no significant
differences were seen for stroke (n=13; hazard ratio 1.92, 95%
confidence interval 0.59 to 6.22) or cardiovascular events (n=25; 0.78,
0.36 to 1.72). Differences were seen for total mortality (47 deaths; hazard
ratio 0.48, 0.26 to 0.87; P=0.02) and cardiovascular mortality (11 deaths;
0.19, 0.04 to 0.87; P=0.03).
Conclusion Very elderly patients with hypertension may gain immediate
benefit from treatment. Sustained differences in reductions of total
mortality and cardiovascular mortality reinforce the benefits and support
the need for early and long term treatment.
Trial registration Clinical trials NCT00122811.
Correspondence to N Beckett n.beckett@imperial.ac.uk
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Introduction
Hypertension remains a risk factor for cardiovascular mortality
and morbidity in very elderly people.1 However, before the
results of the Hypertension in the Very Elderly Trial (HYVET),
uncertainty existed about the benefits and risks associated with
the treatment of very elderly people with hypertension.2 3
HYVET was stopped early by the independent Trial Steering
Committee and DataMonitoring Committee owing to evidence
of a reduction in mortality with active treatment. Despite the
short follow-up during the main trial, with a median follow-up
of 1.8 years (mean 2.1 years), clear evidence of benefit from
active treatment was found. Total mortality was reduced by
21% (95% confidence interval 4% to 35%; P=0.019) and
cardiovascular events (cardiovascular mortality, non-fatal
myocardial infarction, non-fatal stroke, and non-fatal heart
failure) by 34% (18% to 47%; P<0.001).4 No evidence of an
adverse effect from the treatment used in the trial was seen;
significantly fewer serious adverse events occurred with active
treatment, and no suggestion of a deterioration in cognitive
function or an increase in fractures was seen.5 6
Extended follow-up in the Syst-Eur trial suggested that earlier
intervention provided greater benefit in younger elderly people
with hypertension.7 The HYVET Steering Committee agreed
that a one year open label extension to run seamlessly from the
end of the main trial might provide additional information to
that obtained during the main trial. In particular, people
speculated whether early benefits would be seen in such an
elderly group. Additional safety information would also be
obtained. We report here the main findings from the trial
extension.
Methods
The detailed protocol for HYVET has been published.8 9 In brief,
it was a randomised, double blind, placebo controlled trial in
195 centres in 13 countries in western and eastern Europe,
China, Australasia, and Tunisia.
To be eligible for entry into the main trial, participants had to
be aged 80 years or over with sustained levels of systolic blood
pressure of 160 mm Hg or above over a two month placebo
run-in phase. The independent trial Steering Committee
terminated the main trial in July 2007 for ethical reasons, as the
independent Data Monitoring Committee noted a significant
reduction in all cause mortality in participants on active
treatment at the second interim analysis. All final visits related
to the main trial were completed by 12 October 2007. The final
visit was counted as the entry visit to the extension.
To be eligible for entry into the extension, participants simply
needed to be on double blind treatment at the time of their final
visit. No other exclusion criteria for the extension were
considered. During the main trial, participants who reached the
primary or secondary end points (apart from myocardial
infarction, heart failure, and skeletal fracture) were withdrawn
from double blind treatment; even if they were followed up on
open label drug after the event, they would not have been
eligible for the extension. In the end, no participant who entered
the extension had reached an end point during the main trial.
At the start of the trial, blood pressures were recorded with
either a mercury sphygmomanometer or a validated automated
device; by the end, most centres were using an automated device.
At the start of the trial in 2000, the average seated diastolic
blood pressure had to be 90-109 mmHg, but in 2003 a protocol
amendment relaxed this criterion to less than 110 mm Hg,
allowing the inclusion of patients with isolated systolic
hypertension; the standing systolic blood pressure criterion
remained the same at 140 mm Hg or above.
The treatment steps used in the main trial were indapamide SR
1.5 mg alone (step I), then indapamide SR plus perindopril 2
mg (step II), and finally indapamide SR plus perindopril 4 mg
(step III) (or corresponding matching placebos). At the start of
the one year extension, all participants were restarted at the first
step irrespective of the level of treatment under double blind
follow-up. At the time of the start of the extension and for four
months afterwards (until the freezing of the database for the
main trial), the coordinating centre was not supplied with the
code to break the blind, so local investigators were not informed
whether participants had previously been on active or placebo
drug. Titration of trial drug was encouraged to achieve the goal
of systolic blood pressure below 150mmHg and diastolic blood
pressure below 80 mm Hg. The use of additional
antihypertensive agents at the discretion of the local investigator
was allowed if the target was not achieved, but only in the
extension.
Participants provided written informed consent before starting
the extension. For those who were illiterate, an independent
witness signed the consent form.
Data collection
Baseline characteristics were collected during the placebo run-in
period. After randomisation, participants were seen at least every
three months during the first year and at least every six months
thereafter. During the one year extension, visits took place every
three months. At the end of the double blind phase and at the
end of the one year extension, we collected information on
current diseases, drug treatment, blood pressure, biochemistry
(sodium, potassium, urea, creatinine, glucose, uric acid)
cholesterol (total and high density lipoprotein), and haematology
(haemoglobin, haematocrit). At three and six monthly visits,
only information on current diseases, drug treatment, and blood
pressure was collected. All final visits for the one year extension
were completed by 12 October 2008.
End points
During the extension, the same endpoint data were collected as
during the main trial. These included all strokes (fatal and
non-fatal, but not transient ischaemic attacks), total mortality,
cardiovascular mortality, cardiac mortality, and mortality from
stroke. An independent committee blinded to previous treatment
allocation reviewed all possible end points by using predefined
definitions as stated in the protocol.8 Events were classified as
cardiovascular or non-cardiovascular. Cardiacmortality included
fatal myocardial infarction, fatal heart failure, and sudden death.
Cardiovascular events consisted of cardiovascular mortality,
non-fatal myocardial infarction, non-fatal stroke, and non-fatal
heart failure.
Data monitoring and statistical analysis
The same independent data monitoring committee oversaw the
one year extension. The sample size for the original trial was
powered on the primary end point of all strokes.8 As the main
trial stopped early and all participants returned for final visits,
consent for participation in an extension could be obtained at
this visit. This maximised the potential for including as many
patients as possible for further follow-up. At this time, final
data were being collected and cleaned, so the exact rates and
differences between the two original groups were not known.
The code for breaking of the blind was not provided to the
coordinating centre until five months after the final visits, so
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we could not do power calculations on the basis of the collected
data. Given this, and that the existing trial was to run seamlessly
into the extension, we did not do revised power calculations.
No further follow-up data were collected on participants on
open label drug at the time of the final main trial visits. As only
those participants who were on double blind treatment were
recruited into the one year extension, we did not consider it
appropriate to combine the data from the one year extension
with that from the main trial. The data from the one year
extension were thus considered in isolation, comparing
participants previously on active treatment with those previously
on placebo treatment.
We calculated patient years from the date of starting active
treatment in the one year extension until death or the last
available visit. Participants were free to withdraw from the
extension should they wish, but no protocol defined withdrawal
events existed for the extension.
We compared means of continuous variables by z test,
proportions by χ2 test, and incidence rates by log rank test. We
used the Kaplan-Meier method to estimate cumulative incidence
curves. We took a P value of 0.05 to be significant. For
participants with more than one end point, we used time to the
first relevant end point in each analysis. We adjusted results for
all stroke, total, and cardiovascular mortality for sex, age,
baseline seated systolic blood pressure, and cardiovascular
disease before randomisation to the main trial. We calculated
hazard ratios with a Cox proportional model. We checked the
proportional hazard assumption by plotting the Schoenfeld
residuals. All reported P values are two sided and not adjusted
for multiple testing. We used SAS version 9.1.3 for data
management and analyses.
Results
At the end of the main HYVET trial, 1882 participants were on
double blind treatment. Of these, 1009 were receiving active
trial treatment and 873were receiving placebo (fig 1⇓). Of these,
1712 (91%) consented to enter the one year extension—924
(54%) of these were taking active treatment and 788 (46%) were
taking placebo. The participation rates were similar at 91.6%
for active treatment and 90.3% for placebo. No additional
information was collected on the 170 participants (85 in each
group) who did not consent to enter the open label extension or
the 220 participants who were on open label treatment at the
end of the main trial.
Participants who entered the extension were mostly from eastern
Europe (n=493) and China (n=1144). The rest were fromwestern
Europe, Australasia, or Tunisia. The participation rates were
similar in most countries, ranging from 73% to 96%.
Table 1⇓ shows the characteristics of participants who did and
did not enter the one year extension, at the time of entry. Those
who entered the extension were significantly younger than those
who did not, and they had higher systolic blood pressure, lower
total cholesterol, and lower serum creatinine at the end of the
main trial. The biochemical differences are likely to reflect the
higher participation by Chinese people. Compared with the
baseline characteristics at the start of the main trial,4 people
entering the extension were on average 1.5 years older with
slightly higher serum creatinine; they had lower average blood
pressure and body mass index and a lower prevalence of
orthostatic hypotension, diabetes mellitus, and smoking but
similar heart rate, serum uric acid concentration, and total
cholesterol and high density lipoprotein cholesterol.
Among participants who entered the extension, 235 (25%) of
those receiving active treatment were on indapamide alone (step
I), 262 (28%) were on indapamide SR and perindopril 2 mg
(step II), and 416 (45%) were on indapamide SR and perindopril
4 mg (step III) at the end of the double blind phase. The
corresponding numbers for the placebo group were 129 (16%),
114 (14%), and 538 (68%). All patients were restarted on
indapamide alone at the start of the extension, irrespective of
what they were taking at the end of the double blind phase. By
six months, little difference existed in the number at any
particular treatment step between participants previously taking
active drug and those previously taking placebo. Of those
previously taking active drug, 239 (27%), 290 (33%), and 346
(39%) were at steps I, II, and III compared with 183 (25%), 212
(28%), and 346 (46%) of those previously taking placebo. At
the end of the one year extension, the numbers were also
similar—213 (25%), 182 (21%), and 465 (53%) for those
previously on active treatment and 160 (22%), 149 (21%), and
412 (57%) for those previously taking placebo. Although
additional blood pressure lowering treatment was allowed in
the extension to reach the target pressure, the number taking
such drugs in addition to the trial drugs was small at 16 (0.9%)
at six months and 31 (1.8%) after one year. Adherence to trial
drugs was high on the basis of the reported number of days that
drug was missed, with an overall rate of adherence of 99%.
At the end of the double blind phase, the mean sitting blood
pressure was 145.0/76.6 mm Hg in participants on active drug
who went into the extension and 159.3/80.8 mmHg in those on
placebo (P<0.001), a difference of 14.3/4.2 mm Hg. By six
months, the difference in blood pressure was not statistically
different between those previously on active treatment and those
previously on placebo (1.3/0.6 mm Hg); the mean blood
pressures in the groups were 145.3/76 mm Hg and 146.6/76.6
mm Hg (fig 2⇓). This difference remained minimal until the
end of the extension, when the blood pressure was 142.8/76.2
mmHg in participants previously on active drug and 143.8/76.4
mm Hg in those previously on placebo, a difference of 1.0/0.2
mm Hg.
During the one year extension, 47 participants died (11 of the
deaths were considered to be cardiovascular) and 44 withdrew
from follow-up. Two patients were considered lost to follow-up,
and we censored their data at the time of their last visit. At the
end of follow-up, 1619 participants were alive and 1682 patient
years of follow-up had been accrued.
For the primary end point (fatal and non-fatal stroke), 13 events
occurred during the extension, with no significant difference
between participants previously on active treatment and those
previously on placebo (hazard ratio 1.92, 95% confidence
interval 0.59 to 6.22; P=0.28) (table 2⇓). Similarly, we found
no differences between the two groups for heart failure events
(hazard ratio 0.28, 0.03 to 2.73; P=0.28) or the composite end
point of cardiovascular events (0.78, 0.36 to 1.72; P=0.55). We
found differences in total mortality (hazard ratio 0.48, 0.26 to
0.87; P=0.02) and cardiovascular mortality (0.19, 0.04 to 0.87;
P=0.03). Adjustment for age, sex, baseline sitting systolic blood
pressure, and previous cardiovascular disease did not change
the results.
The local investigators did not report any serious adverse drug
reactions during the extension period. In total, 99 serious adverse
events were reported—53 in participants previously treated with
placebo and 46 in those previously on active treatment (P=0.12).
The mean biochemical changes over the one year extension
were all small and not clinically significant in the two groups.
We noted statistical differences between the two groups for
serum sodium (mean decrease 0.6 mmol/L for placebo and 0.1
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mmol/L for active treatment; P=0.04) and for serum uric acid
(mean increase 15.5 µmol/L for placebo and 0.7 µmol/L for
active treatment; P=0.001).
Comparing the results for the extension against those for the
main trial, we noted that the rates per 1000 patient years were
lower in the extension than in the main trial irrespective of
whether participants had previously been treated with active or
placebo drug (fig 3⇓). For stroke, the rate during the main trial
was 11.7 per 1000 patient years in the active treatment group
and 17.3 per 1000 patient years in the placebo group. The rates
during the extension were 9.9 per 1000 patient years for
participants previously on active treatment and 5.2 per 1000
patient years for those previously on placebo. The difference
during the main trial was significant (P=0.04), unlike during
the extension. Although significant differences in total mortality
remained during the extension, the rates were lower than during
the main trial.
Discussion
The results of the one year open label extension have added to
those of the main HYVET trial. The lack of difference in
incidence of heart failure and stroke between participants
previously receiving active treatment and those previously
receiving placebo suggests that early benefits can be achieved
from treating and controlling blood pressure in very elderly
people with hypertension with the treatment used in the trial.
The fact that differences remained in all cause mortality and
cardiovascular mortality supports the idea that some benefits
from control of blood pressure take longer to accrue and that
early treatment is thus warranted.
Even at the age of 80, average life expectancy can be around
seven years for men and nine years for women.10 Considering
the prevention of adverse cardiovascular events even at this
advanced age is thus appropriate, as a reduction in disability
and maintenance of independence and quality of life would
clearly be of benefit. In HYVET, most participants initially
recruited to the trial did not have established cardiovascular
disease. Participants entering the extension had not reached a
cardiovascular end point during the main trial, so the results of
both studies are most applicable to preventing cardiovascular
events in people free of established cardiovascular disease. The
fact that the differences in cardiovascular events overall between
active treatment and placebo seen in the main trial were lost
within one year of active antihypertensive treatment reinforces
the suggestion that the over 80s should be screened regularly
with a view to treatment if they have sustained blood pressures
of 160 mm Hg or above as they are likely to gain benefits from
early detection.
The difference in blood pressure that existed at the start of the
extension was essentially abolished within six months. As in
the active arm of the trial, most participants (approximately
three quarters) needed combination therapy of indapamide SR
and perindopril at either the 2 mg or 4 mg dosage. Additional
non-trial drugs were needed in only a small number of
participants. The overall achieved mean blood pressure at six
months was 146/76 mm Hg, suggesting that the achievement
of blood pressures below 150/80 mm Hg is possible in most
very elderly people and that such combination treatment is
effective. These results do not answer the question of whether
even lower achieved pressures would be more effective in this
age group, and additional research is needed to determine this.
We saw no suggestion of an increase in serious adverse events
to suggest detrimental effects from such an achieved reduction
in blood pressure. In addition, theminor non-clinically important
biochemical changes seen during the extension support the use
of a combination of sustained release indapamide and low dose
perindopril in such elderly patients with hypertension.
Treatment of hypertension is considered to be life long. Most
clinical trials are of short duration, however, as they have been
designed to test the trial hypothesis within a certain period of
time and powered to do so. Stopping the HYVET trial early
was entirely appropriate, given the clear benefits that were seen.
The additional patient years accrued during the extension
extended the overall exposure to treatment, especially among
participants who were on active drug from the start of the trial.
Given that the event rates were lower in the extension than in
the main trial, this adds weight to the importance of long term
antihypertensive treatment in very elderly people with high
blood pressure. However, people who entered the extension,
despite being on average older than those at entry to the main
trial, seemed to be healthier with lower rates of diabetes and
smoking and lower average blood pressures, and this may have
led to lower event rates. Despite this, differences in total
mortality and cardiovascular mortality remained during the
extension, indicating that reductions in these major end points
are likely to take a longer time to accrue. This was already seen
in the main trial period, with the divergence in event rates
between the randomisation groups gradually increasing over
time.4 Thus, although this seems to be a later benefit from
treatment, it confirms the importance of early and sustained
antihypertensive treatment even in very elderly people.
Comparison with other studies
Other intervention trials in hypertension have also reassessed
the long term outcomes of participants originally included in
the trial. In a 14.3 year follow-up of participants from the
Systolic Hypertension in Elderly Persons (SHEP) trial,
cardiovascular mortality was 15% lower in the original diuretic
treated group than in the group originally treated with placebo.11
Interestingly, the diuretic treated group were more likely to
develop diabetes than were the placebo group (13% v 8.7%)
The patients with diabetes ascertained in the diuretic treated
group had no increase in cardiovascular mortality or all cause
mortality during this follow-up period compared with those
diuretic treated patients who did not develop diabetes during
the trial. No significant changes in blood glucose occurred in
the extension of HYVET, in keeping with the result during the
main trial. In a separate analysis of a subgroup of the SHEP
participants, again followed up for 14 years, patients originally
assigned to active treatment had a 90% lower mortality or
incidence of cardiovascular events compared with patients
originally assigned to placebo.12 The long term benefit from
active treatment was greatest in those patients without baseline
evidence of atherosclerosis, whereas the benefit over placebo
seemed to dissipate in those with baseline evidence of
atherosclerosis. Such extended length of follow-up would not
be relevant for participants recruited to HYVET, given the
average life expectancy. What is most important in
octogenarians with hypertension is that any benefits from
intervention are achieved as soon as possible. Nevertheless,
confirming the longer term sustained benefits from early active
antihypertensive drug treatment among very elderly patients is
also relevant.
The results of the HYVET extension are also in line with those
from the extended follow-up of participants in the Systolic
hypertension in Europe trial (Syst-Eur).7 The Syst-Eur trial was
terminated early and went on to have an open label active
extension that increased the median follow-up from 2 years to
6.1 years. Participants were followed up irrespective of whether
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they were on double blind treatment or in open label follow-up
when the main trial was terminated. This allowed combination
of the extension and the main trial data, unlike in the HYVET
extension. The results from the Syst-Eur extension showed that
immediate treatment compared with delayed treatment reduced
the occurrence of stroke by 28% and cardiovascular
complications by 15%.
Strength and limitations
One of the main limitations of the HYVET extension was that
only participants who were on double blind treatment were
enrolled from the main trial. Differential survival between those
on active and placebo drugs and withdrawal rates in the main
trial meant that the numbers in each group who remained on
double blind treatment at the end of the main trial were not
balanced. Although participants who had received active
treatment during the main trial had similar levels of diabetes,
smoking, and cholesterol, they differed from those who had
received placebo in that they had higher blood pressures and
concentrations of uric acid at the start of the extension period.
The exclusion of patients moved to open label treatment during
the main trial, with no possibility of further information being
obtained if they reached any end points, meant that an analysis
of all participants from the time of randomisation was not
appropriate. Also, comparing the extension results directly with
the main trial results would not be possible. In any case,
combining the data obtained in the extension with those from
the main trial would simply dilute the results seen in the main
trial, as no patient who entered the extension had an end point
before that time. Another limitation is the short length of
follow-up in the extension. Unfortunately, we did not have
resources to do a further long term follow-up among this cohort
of patients. Finally, given the small number of events in the
extension, caution must be exercised in drawing firm
conclusions simply from the extension. The results should be
viewed in the context of those from the main trial as well.
Applicability and generalisability
All octogenarians, irrespective of their blood pressure, are at
high risk of a cardiovascular event owing to their age alone.
That does not mean that all would benefit from antihypertensive
treatment. These results support the treatment of very elderly
people with blood pressures over 160 mm Hg who do not have
cognitive impairment and are not considered to be frail. Further
research is needed before clearer recommendations can be
proposed for other people. Further research is also needed into
whether lowering systolic blood pressure to below 150 mm Hg
in people aged 80 or more is truly beneficial.
In summary, the results from the extension show that the benefit
of the antihypertensive treatment used in HYVET may be
accrued within 12 months even in very elderly people for events
that are very dependent on blood pressure, such as stroke and
heart failure. Benefits in terms of a reduction in mortality and
cardiovascular mortality are likely to take longer to accrue.
People aged 80 or more should have their blood pressure
checked regularly, and if they have sustained levels of 160 mm
Hg or more should be treated in line with the HYVET regimen
with a view to reducing their systolic blood pressure to below
150 mm Hg.
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What is already known on this topic
People aged 80 or more with sustained systolic blood pressures of 160 mm Hg or more benefit from blood pressure lowering treatment
What this study adds
Benefits in terms of a reduction in cardiovascular events appeared within one year of starting treatment
The benefit was achieved by lowering systolic blood pressure to 150 mm Hg; any benefit of lowering blood pressure further cannot be
assumed
Free living, community based octogenarians should be screened for hypertension and offered blood pressure lowering treatment in line
with HYVET
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Tables
Table 1| Characteristics of patients who entered one year extension at start of extension, compared with those who did not enter extension.
Values are mean (SD) unless stated otherwise
Patients who did not enter extension*
(n=170)
Patients who entered extension
Characteristic Previously on placebo (n=788)Previously on active treatment (n=924)
87.4† (4.0)84.6 (4.3)84.9 (3.2)Age (years)
113 (66)491 (62.3)562 (60.8)No (%) female
142.9†/79.8 (19.2/11.6)159.3/80.8 (19.9/10.3)145.0‡/76.6‡ (17.8/10.0)Sitting blood pressure (mm Hg)
141.4†/78.8 (19.0/8.5)156.2/80.2 (19.9/10.7)141.9‡/75.8‡ (19.3/11.2)Standing blood pressure (mm Hg)
6 (4)51 (6.5)42 (4.5)No (%) with orthostatic hypotension§
75.1 (10.6)74.9 (10.8)74.8 (11.5)Heart rate (beats per minute)
11 (6)63 (8.0)64 (6.9)No (%) current smokers
4 (2)30 (3.8)38 (4.1)No (%) with diabetes¶
5.4† (0.8)4.9 (1.0)5.0 (1.0)Total cholesterol (mmol/L)
1.2 (0.3)1.3 (0.4)1.3 (0.4)HDL cholesterol (mmol/L)
102.8† (24.8)91.2 (24.8)91.3 (25.5)Serum creatinine (µmol/L)
254.4 (97.7)274.2 (84.6)299.1‡ (93.4)Uric acid (µmol/L)
24.4 (4.4)23.7 (3.9)23.8 (3.8)Body mass index (kg/m2)
HDL=high density lipoprotein.
*Full data not available for 40 patients.
†Significant difference between patients in extension and those not in extension (P<0.05).
‡Significant difference between patients in extension previously on active treatment and those in extension previously on placebo (P<0.05).
§Drop of >20 mm Hg in systolic blood pressure or >10 mm Hg in diastolic blood pressure on standing.
¶Reported diabetes, taking anti-diabetic treatment, or random blood glucose >11.1 mmol/L.
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Table 2| Main fatal and fatal plus non-fatal outcomes for intention to treat analysis
P valueHazard ratio* (95% CI)
Rate per 1000 patient years (No of events)
End points Previously on active treatmentPreviously on placebo treatment
0.281.92 (0.59 to 6.22)9.89 (9)5.18 (4)Fatal and non-fatal stroke
0.020.48 (0.26 to 0.87)18.6 (17)38.8 (30)All cause mortality
0.130.46 (0.17 to 1.25)6.6 (6)14.2 (11)Non-cardiovascular or unknown cause
0.030.19 (0.04 to 0.87)2.19 (2)11.6 (9)Cardiovascular mortality
0.280.28 (0.03 to 2.73)1.1 (1)3.9 (3)All heart failure
0.550.78 (0.36 to 1.72)13.2 (12)16.9 (13)All cardiovascular events†
*Unadjusted.
†Cardiovascular death, stroke, myocardial infarction, and heart failure.
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Figures
Fig 1 Study profile
Fig 2Mean sitting blood pressure by group (previously treated with placebo and previously on active treatment) of participants
in extension for systolic blood pressure (top panel) and diastolic blood pressure (bottom panel). E0=visit at start of extension;
E3, E6, E12=visits 3, 6, and 12 months after entry into extension
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Fig 3 Rates per 1000 patient years in main trial and extension for stroke (top panel) and total mortality (bottom panel)
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